Circulating tumor DNA profiling by next generation sequencing reveals heterogeneity of crizotinib resistance mechanisms in a gastric cancer patient with MET amplification

Crizotinib has been used to counter MET gene amplification in a number of different human malignancies. Transient response to crizotinib in MET-amplified gastric cancer has been reported, but the mechanisms of resistance are not well studied. Here, we reported a stage IV gastric cancer patient with...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Main Authors: Du, Juan, Wu, Xue, Tong, Xiaoling, Wang, Xiaonan, Wei, Jia, Yang, Yang, Chang, Zhili, Mao, Yu, Shao, Yang W, Liu, Baorui
Formato: Artigo
Idioma:Inglês
Publicado: Impact Journals LLC 2017
Assuntos:
Research Paper
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5432256/
https://ncbi.nlm.nih.gov/pubmed/28460431
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.15457
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares